AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)
World

China exploring ways to mix different COVID vaccines to improve efficacy

  • Gao says one option is to adjust the dosage, the interval between doses, or increase the number of doses while the second route is to mix vaccines that use different technologies
  • More attention should be given to developing mRNA vaccines as the technology provided an opportunity for breakthroughs in treating all kinds of illnesses: health expert
Published April 11, 2021

(Karachi) In a major development, China is now exploring ways to mix different Covid-19 vaccines to address the relatively low efficacy of its existing jabs, local media reported on Sunday.

Top Chinese health expert Dr Gao Fu, who heads the Centre for Disease Control and Prevention, said that the authorities should solve the low efficacy issue of existing vaccines and try to improve them.

He said that one option is to adjust the dosage, the interval between doses, or increase the number of doses. "The second route is to mix vaccines that use different technologies," he maintained.

He stated that researchers should not ignore mRNA vaccines just because there are already several coronavirus jabs in the country. "More attention should be given to developing mRNA vaccines as the technology provided an opportunity for breakthroughs in treating all kinds of illnesses such as infectious diseases, HIV/AIDS, cancer and genetic diseases," Gao pointed out.

Currently, none of China's jabs conditionally approved for the market are mRNA vaccines, but products that use the technology include those by US pharma giant Pfizer and German start-up BioNTech, as well as by Moderna.

Three Chinese inactivated vaccines are currently available, including one made by Sinovac. Its vaccines had an efficacy rate of 50.4 percent in trials in Brazil, and 83.5 percent from separate trials in Turkey.

Sinopharm says its two inactivated vaccines have efficacy rates of 79 percent and 72.5 respectively, while CanSino says its product has an efficacy rate of 75 percent.

Comments

Comments are closed.